Litcius/Paper detail

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

Kuan‐Wei Huang, Fu‐Fei Hsu, Jiantai Timothy Qiu, Guann-Jen Chern, Yi-An Lee, Chih‐Chun Chang, Yu‐Ting Huang, Yun‐Chieh Sung, Cheng-Chin Chiang, Rui-Lin Huang, Chu-Chi Lin, Trinh Kieu Dinh, Hsi‐Chien Huang, Yu-Chuan Shih, Donia Alson, Chun‐Yen Lin, Yung‐Chang Lin, Po-Chiao Chang, Shu‐Yi Lin, Yunching Chen

2020Science Advances255 citationsDOIOpen Access PDF

Abstract

T cells, augmented the efficacy of cancer vaccine immunotherapy, and suppressed HCC progression. Our work presents nanotechnology-enabled dual delivery of siRNA and plasmid DNA that selectively targets and reprograms the immunosuppressive tumor microenvironment to improve cancer immunotherapy.

Topics & Concepts

Dual (grammatical number)Cancer therapyCancerNanoparticleNanotechnologyCancer researchMedicineComputational biologyBiologyMaterials scienceInternal medicinePhilosophyLinguisticsImmunotherapy and Immune ResponsesRNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer | Litcius